Alpha-9 Oncology

Bio Health Biotechnology Medical Product Research

2 open2 filled

Vancouver, British Columbia, CanadaFounded 20193+ employees$259.0M raisedGrowthPrivate

Last round: series c · $175M · Oct 2024(4 rounds total)

Founded by David Perrin“Clinical-stage radiopharma pipeline of peptide-based, best-in-class oncology therapies”

Backed by(17 investors)

Lightspeed Venture PartnersAscenta CapitalLongitude CapitalNextech InvestSamsara BioCapitalLumira VenturesJanus Henderson InvestorsAberdeenFrazier Life SciencesBiotechnology Value FundRA Capital ManagementAndreessen HorowitzDelos CapitalGeneral Catalyst

Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.